Principal Financial Group Inc. trimmed its position in shares of Medidata Solutions, Inc. (NASDAQ:MDSO) by 41.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 251,429 shares of the company’s stock after selling 176,872 shares during the period. Principal Financial Group Inc. owned approximately 0.44% of Medidata Solutions worth $19,661,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in MDSO. Canada Pension Plan Investment Board acquired a new stake in shares of Medidata Solutions during the 1st quarter worth $2,261,000. Great West Life Assurance Co. Can increased its holdings in shares of Medidata Solutions by 6.4% during the 1st quarter. Great West Life Assurance Co. Can now owns 77,373 shares of the company’s stock worth $4,463,000 after buying an additional 4,665 shares during the last quarter. Advisors Asset Management Inc. increased its holdings in shares of Medidata Solutions by 80.9% during the 1st quarter. Advisors Asset Management Inc. now owns 19,317 shares of the company’s stock worth $1,114,000 after buying an additional 8,638 shares during the last quarter. BNP Paribas Arbitrage SA increased its holdings in shares of Medidata Solutions by 9.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 11,171 shares of the company’s stock worth $644,000 after buying an additional 997 shares during the last quarter. Finally, Comerica Bank increased its holdings in shares of Medidata Solutions by 5.0% during the 1st quarter. Comerica Bank now owns 61,305 shares of the company’s stock worth $3,997,000 after buying an additional 2,936 shares during the last quarter. Institutional investors and hedge funds own 97.53% of the company’s stock.
WARNING: This piece was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/09/14/medidata-solutions-inc-mdso-shares-sold-by-principal-financial-group-inc.html.
Shares of Medidata Solutions, Inc. (MDSO) opened at 74.46 on Thursday. The firm has a market capitalization of $4.22 billion, a P/E ratio of 120.29 and a beta of 1.81. The company has a 50-day moving average price of $74.82 and a 200 day moving average price of $69.64. Medidata Solutions, Inc. has a one year low of $46.10 and a one year high of $85.92.
Medidata Solutions (NASDAQ:MDSO) last released its quarterly earnings results on Tuesday, July 18th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. The business had revenue of $137.41 million for the quarter, compared to the consensus estimate of $134.28 million. Medidata Solutions had a net margin of 7.07% and a return on equity of 11.14%. Medidata Solutions’s revenue for the quarter was up 19.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.24 EPS. Analysts expect that Medidata Solutions, Inc. will post $1.28 earnings per share for the current fiscal year.
In other news, COO Michael L. Capone sold 5,000 shares of the firm’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $74.53, for a total transaction of $372,650.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 5.80% of the stock is currently owned by company insiders.
MDSO has been the subject of a number of research analyst reports. Zacks Investment Research downgraded Medidata Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, May 17th. Bank of America Corporation initiated coverage on Medidata Solutions in a report on Tuesday, June 6th. They set a “buy” rating and a $85.00 price objective for the company. BidaskClub downgraded Medidata Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, June 14th. Morgan Stanley set a $74.00 price objective on Medidata Solutions and gave the stock a “buy” rating in a report on Wednesday, June 14th. Finally, SunTrust Banks, Inc. upped their price objective on Medidata Solutions from $80.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, June 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. Medidata Solutions currently has a consensus rating of “Buy” and a consensus target price of $82.91.
Medidata Solutions Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.